Al­ny­lam pro­vides long-term look at Oxlu­mo, aim­ing to fur­ther carve out stake in PH1 mar­ket

Al­ny­lam is al­ready a leader in RNAi ther­a­py, hav­ing se­cured three ap­provals in the field with a fourth po­ten­tial­ly on the way. Now, the drug­mak­er is re­leas­ing new da­ta on one of its OK’ed med­i­cines that boost its long-term safe­ty pro­file.

As part of con­tin­u­ing analy­ses from its ran­dom­ized, place­bo-con­trolled Phase III tri­al for Oxlu­mo (lumasir­an), Al­ny­lam re­port­ed pos­i­tive 12-month fol­low-up da­ta in tri­al par­tic­i­pants with pri­ma­ry hy­per­ox­aluria type 1. New re­sults have shown the drug was as­so­ci­at­ed with im­prov­ing cal­ci­um de­posit lev­els in one or both kid­neys, or nephro­cal­ci­nosis, rel­a­tive to base­line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER